Approved a new antianginal agent

Cardiosource: "New Agent Approved
In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, patented in 1986 as a new molecular entity, is approved for use as combination therapy when angina is not adequately controlled with other antianginal agents.

Ranolazine was originally thought to have its greatest effect as a partial fatty oxidation inhibitor.12 Fatty acids rise precipitously in response to stress, including acute myocardial ischemia. " /.../